To hear about similar clinical trials, please enter your email below
Trial Title:
Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma
NCT ID:
NCT05576519
Condition:
Ovarian Carcinoma
Conditions: Official terms:
Carcinoma
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Conditions: Keywords:
Ovarian carcinoma
CSCs
EpCAM
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Retrospective
Summary:
Cancer stem cells (CSCs) can undergo self-renewal and differentiation. EpCAM is a 40-kDa
type I transmembrane glycoprotein composed of a large extracellular domain, one
transmembrane region, and a small intracellular domain of 26 amino acids. Recent insights
revealed that it is involved in promoting cancer cell proliferation, migration, and
invasiveness. It is used as a diagnostic and prognostic marker. EpCAM has also recently
been identified as a marker for CSCs.
Detailed description:
Ovarian carcinoma is one of most frequent cancer in women worldwide. Epithelial ovarian
carcinoma is a group of neoplasms with different histologic pictures. Serous carcinoma is
the most common type.
Cancer stem cells (CSCs) can undergo self-renewal and differentiation. EpCAM is a 40-kDa
type I transmembrane glycoprotein composed of a large extracellular domain, one
transmembrane region, and a small intracellular domain of 26 amino acids. It is
abundantly expressed by the majority of human epithelial carcinomas, including
colorectal, breast, lung, prostate, ovarian, and endometrial cancers. it is overexpressed
in various neoplasms. Recent insights revealed that it is involved in promoting cancer
cell proliferation, migration, and invasiveness. It is used as a diagnostic and
prognostic marker. EpCAM has also recently been identified as a marker for CSCs.
Criteria for eligibility:
Study pop:
Fifty paraffin blocks of EOC collected from the archive of Pathology Department of Sohag
Faculty of Medicine during the time period from June 2017 to June 2022.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patients with epithelial ovarian carcinoma and underwent surgery
Exclusion Criteria:
-
- Cases received pre-operative chemotherapy or radiotherapy.
- Cases with insufficient clinical data.
Gender:
Female
Minimum age:
N/A
Maximum age:
N/A
Locations:
Facility:
Name:
Faculty of Medicine, Sohag University
Address:
City:
Sohag
Country:
Egypt
Status:
Recruiting
Facility:
Name:
Faculty of Medicine
Address:
City:
Sohag
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
Rasha Mokhtar, Lecturer
Phone:
01158408563
Start date:
June 1, 2017
Completion date:
December 30, 2022
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05576519
